DXR vs. DRIO, LUCD, LNSR, XAIR, CTSO, CTCX, APYX, ICCM, NSPR, and MODD
Should you be buying Daxor stock or one of its competitors? The main competitors of Daxor include DarioHealth (DRIO), Lucid Diagnostics (LUCD), LENSAR (LNSR), Beyond Air (XAIR), Cytosorbents (CTSO), Carmell (CTCX), Apyx Medical (APYX), IceCure Medical (ICCM), InspireMD (NSPR), and Modular Medical (MODD). These companies are all part of the "surgical & medical instruments" industry.
DarioHealth (NASDAQ:DRIO) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership, community ranking and analyst recommendations.
Daxor has lower revenue, but higher earnings than DarioHealth.
In the previous week, DarioHealth had 9 more articles in the media than Daxor. MarketBeat recorded 10 mentions for DarioHealth and 1 mentions for Daxor. DarioHealth's average media sentiment score of 1.18 beat Daxor's score of 0.53 indicating that Daxor is being referred to more favorably in the news media.
DarioHealth has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. Comparatively, Daxor has a beta of -0.45, suggesting that its share price is 145% less volatile than the S&P 500.
DarioHealth received 238 more outperform votes than Daxor when rated by MarketBeat users.
DarioHealth presently has a consensus price target of $4.05, indicating a potential upside of 113.72%. Given Daxor's higher possible upside, equities research analysts clearly believe DarioHealth is more favorable than Daxor.
33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 15.7% of DarioHealth shares are owned by insiders. Comparatively, 60.6% of Daxor shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Daxor has a net margin of 0.00% compared to Daxor's net margin of -282.38%. DarioHealth's return on equity of 0.00% beat Daxor's return on equity.
Summary
DarioHealth beats Daxor on 7 of the 12 factors compared between the two stocks.
Get Daxor News Delivered to You Automatically
Sign up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
